Tachyon Therapeutics

About:

Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.

Top Investors: Khosla Ventures, Red Tree Venture Capital, California Institute for Regenerative Medicine, Veblen Ventures

Description:

Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer. The company is currently conducting Phase 1 clinical research in patients with advanced cancer to assess the safety, pharmacokinetics, and anti-tumor effectiveness of TACH101. The programs will be advanced in a timely, innovative, high-quality, and scientifically sound manner.

Total Funding Amount:

$18.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)tachyontx.com

Founders:

Mike Clarke

Number of Employees:

1-10

Last Funding Date:

2023-03-01

IPO Status:

Private

Industries: